Intellipharmaceutics (IPCI) Toronto Facility Completes cGMP, Pre-Approval Inspection Process
Tweet
Share
E-mailGet Alerts IPCI Hot Sheet
Join SI Premium – FREE
Intellipharmaceutics International Inc. (Nasdaq: IPCI) reports its Toronto-based oral solid dosage forms manufacturing facility has completed a cGMP and pre-approval inspection process by the U.S. Food and Drug Administration and has been granted "acceptable" status under the Agency's strict regulatory guidelines.
Intellipharmaceutics' Toronto manufacturing facility was previously inspected and approved by the Canadian regulatory authorities, Health Canada.
Intellipharmaceutics currently has six Abbreviated New Drug Applications being reviewed by the FDA for the purpose of achieving regulatory approval.
Intellipharmaceutics' Toronto manufacturing facility was previously inspected and approved by the Canadian regulatory authorities, Health Canada.
Intellipharmaceutics currently has six Abbreviated New Drug Applications being reviewed by the FDA for the purpose of achieving regulatory approval.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BioNTech ends colorectal cancer mRNA therapy trial early
- United Therapeutics presents drug trial data at two European congresses
- Cyabra lands six-figure deal with gaming firm to monitor online activity
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
